Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q02127
UPID:
PYRD_HUMAN
Alternative names:
Dihydroorotate oxidase
Alternative UPACC:
Q02127; A8K8C8; Q6P176
Background:
Dihydroorotate dehydrogenase (quinone), mitochondrial, also known as Dihydroorotate oxidase, plays a pivotal role in pyrimidine biosynthesis. It catalyzes the conversion of dihydroorotate to orotate, a critical step in the de novo pathway of UMP (uridine monophosphate) production, essential for DNA and RNA synthesis.
Therapeutic significance:
Postaxial acrofacial dysostosis (POADS) is linked to mutations affecting this enzyme, highlighting its importance in human development and disease. Understanding the role of Dihydroorotate dehydrogenase could open doors to potential therapeutic strategies for treating POADS and related disorders.